Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1

By N. Gupta, X. Su, B. Popov, J. W. Lee, V. Serikov, Michael A. Matthay. Journal of Immunology, 2007

920 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/19a4c46009e6172af016640b2ecd1489a5cecfb0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael A. Matthay
2. R. Zemans
3. W. Fibbe
4. Maria Ester Bernardo
5. Christopher M. Waters

In Pulmonary and Respiratory Medicine

1. R. Zemans
2. Michael A. Matthay
3. Elizabeth Johnson
4. N. Gupta
5. V. Serikov
6. W. Fibbe
7. Maria Ester Bernardo

Citations in the corpus

• Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL-37 (2010, methodology): “5A–5D), reflecting the immunomodulatory properties of MSCs [18–22].”
• The Acute Respiratory Distress Syndrome: Pathogenesis and Treatment (2011, background): “In one study from our research group, intratracheal MSCs were effective at reducing pulmonary edema and mortality in mice that had been treated with high-dose intratracheal endotoxin (5 mg kg−1) (74).”
• Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment (2010, positive): “Gupta and colleagues((89)) reported the MSCs’ anti-inflammatory properties in both in vivo and in vitro.”
• Epithelial repair mechanisms in the lung. (2010, background): “Other groups have demonstrated attenuation of endotoxininduced lung injury utilizing BMSC in mice (57, 194).”
• Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs (2019, background): “Moreover, no decrease in TNF-α levels and no increase in IL-10 levels could be observed, neither in plasma nor in fluid from bronchoalveolar lavage (22).”
• Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer (2017, background): “We and others have reported that MSCs improve survival, reduce inflammation and enhance bacterial clearance in pre-clinical models of lung injury((7-14)).”
• Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung (2009, background): “As suggested by recent mouse injury models [intra-tracheal LPS (23), intra-tracheal bleomycin (28), cecal ligation and puncture (19)], the secretion of pro- and anti-inflammatory cytokines, such as IL-1RA and IL-10, may account for some beneficial effects of MSCs.”
• Mesenchymal stromal cells: sensors and switchers of inflammation. (2013, positive): “Similar observations were made in a model of endotoxininduced lung injury, in which intrapulmonary delivery of mouse BM-MSCs decreased the production of TNF-a and chemokine ligand CXCL2 and increased the production of IL-10 by alveolar macrophages (Gupta et al., 2007).”
• Coronavirus disease 2019 (COVID-19): current status and future perspectives (2020, background): “injury and ARDS by suppressing infiltration of immune cells to pulmonary tissues and pro-inflammatory cytokine secretion [91-94].”
• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, neutral): “However, it eventually became evident that MSCs could mediate robust tissue repair, but exhibited low or/and transient engraftment into the injured tissue [75,76].”